213 related articles for article (PubMed ID: 27368038)
1. CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents.
Choi IJ; Koh YS; Park MW; Her SH; Choi YS; Park CS; Park HJ; Kim PJ; Chung WS; Kim HS; Shin JG; Seung KB; Chang K
Medicine (Baltimore); 2016 Jun; 95(26):e4049. PubMed ID: 27368038
[TBL] [Abstract][Full Text] [Related]
2. Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
Nishio R; Shinke T; Otake H; Nakagawa M; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Kuroda M; Hirata K
Thromb Res; 2013 Nov; 132(5):558-64. PubMed ID: 24080149
[TBL] [Abstract][Full Text] [Related]
3. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
[TBL] [Abstract][Full Text] [Related]
4. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
5. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
7. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T
Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531
[TBL] [Abstract][Full Text] [Related]
8. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
[TBL] [Abstract][Full Text] [Related]
9. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
Arima Y; Hokimoto S; Akasaka T; Mizobe K; Kaikita K; Oniki K; Nakagawa K; Ogawa H
J Cardiol; 2015 Jun; 65(6):494-500. PubMed ID: 25156215
[TBL] [Abstract][Full Text] [Related]
11. Characterization of patients with angioscopically-detected in-stent mural thrombi – genetics of clopidogrel responsiveness and generations of drug-eluting stents.
Ichikawa M; Takei Y; Hamasaki T; Kijima Y
Circ J; 2015; 79(1):85-90. PubMed ID: 25744629
[TBL] [Abstract][Full Text] [Related]
12. Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome.
Song PS; Hahn JY; Kim DI; Song YB; Choi SH; Choi JH; Ryu DR; Hur SH; Jeong JO; Park HS; Kim HS; Gwon HC
Eur J Intern Med; 2015 Sep; 26(7):521-7. PubMed ID: 26153337
[TBL] [Abstract][Full Text] [Related]
13. Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
Wang Y; Cai H; Zhou G; Zhang Z; Liu X
J Neurol Sci; 2016 Oct; 369():216-219. PubMed ID: 27653892
[TBL] [Abstract][Full Text] [Related]
14. Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention.
Lee SH; Jeong YH; Hong D; Choi KH; Lee JM; Park TK; Yang JH; Hahn JY; Choi SH; Gwon HC; Jeong MH; Kim BK; Joo HJ; Chang K; Park Y; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Kim HS; Kim MH; Lim DS; Shin ES; Song YB;
JACC Cardiovasc Interv; 2023 Apr; 16(7):829-843. PubMed ID: 37045504
[TBL] [Abstract][Full Text] [Related]
15. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
Jiang M; You JH
Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
Carlquist JF; Knight S; Horne BD; Huntinghouse JA; Rollo JS; Muhlestein JB; May H; Anderson JL
Thromb Haemost; 2013 Apr; 109(4):744-54. PubMed ID: 23364775
[TBL] [Abstract][Full Text] [Related]
17. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
18. Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents.
Loh JP; Torguson R; Pendyala LK; Omar A; Chen F; Satler LF; Pichard AD; Waksman R
Am J Cardiol; 2014 Jun; 113(12):1968-76. PubMed ID: 24767975
[TBL] [Abstract][Full Text] [Related]
19. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
[TBL] [Abstract][Full Text] [Related]
20. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G
Platelets; 2015; 26(6):558-62. PubMed ID: 25207801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
